Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Investor Presentation (June 2016)
13 slides from Aft Pharmaceuticals's investor presentation, Jun 3, 2016
Slide 1: AFT Pharmaceuticals NZX Presentation
For personal use only AFT PHARMACEUTICALS NZX Presentation June 2016
Slide 2: Important Notice
For personal use only IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New
Slide 3: Presenting Today
For personal use only PRESENTING TODAY . . . Dr Hartley Atkinson Founded AFT in 1997 along with his wife, Marree Previously Sales & Marketing Director, Medical Director, Founder and Chief Executive Officer Product Manager and Medical Manager at Swiss multinational pharmaceutical company, Roche Malco
Slide 4: Summary of AFT Business
SUMMARY OF AFT BUSINESS Established Business [1997] and growing AU & NZ [19% CAGR Last 10 Years] Growing business in Singapore & Malaysia For personal use only Growing outside ANZ & SE Asia via Distributors & Licensees Clinical Studies of Key Innovative Products • Maxigesic Tablets – Target Market U
Slide 5: FY2016 Highlights
For personal use only FY2016 HIGHLIGHTS 98 countries that Maxigesic is licensed in 4 countries that Maxigesic is launched and sold in 12 number of clinical studies AFT will have running in FY2017 $65.8m total income for FY2016* $28.1m available cash as at 31 March 2016 Investor Presentation 4 * Tota
Slide 6: Accelerating Clinical Study Program
ACCELERATING CLINICAL STUDY PROGRAM • 12 studies across the AFT portfolio For personal use only • 1500+ patients • 7 countries - Australia, Jordan, Mexico, New Zealand, Russia, United Kingdom, United States • Clinical Trials for Maxigesic oral dose forms are well underway with studies running in Amm
Slide 7: Maxigesic Update
MAXIGESIC UPDATE UK – launch pending soon Eastern Europe – launch pending soon Italy – successful launch and first royalty booked in May 2016 For personal use only UAE – sales doubling in second year of sales Singapore – launch in June 2016 Australia – down scheduled to S2 – can be advertised – code
Slide 8: Maxigesic Highlights
MAXIGESIC HIGHLIGHTS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the For personal use only number of countries to 98 as at 31 March 2016. Clinical Trials for Maxigesic oral dose forms are well underway with studies running in Amman
Slide 9: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2000 – FY2016 70 For personal use only 60 Operating revenue (NZ$m) 10 year C AGR: 19% 50 40 30 20 10 - 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 FY2015 Operating revenue by region FY2016 Operating revenue by region Southea
Slide 10: Financial Performance – Revenue by Region and Channel
FINANCIAL PERFORMANCE – REVENUE BY REGION AND CHANNEL Operating revenue by region, FY2014 – FY2016 For personal use only NZ$000's, year ended 31 March 2014 % of total 2015 % of total 2016 % of total Australia 20,035 40.9% 26,324 46.8% 31,224 48.8% YoY Growth - 31.4% 18.6% New Zealand 28,790 58.8% 29
Slide 11: NasoSURF Nebuliser
NASOSURF NEBULISER DRUG DELIVERY AND TREATMENT SINUS CONDITIONS For personal use only A handheld ultrasonic nasal mesh nebuliser for the The NasoSURF Nebuliser has desirable features Product over currently marketed nebulisers, which are not intranasal delivery of medication and treatment of descript
Slide 12: NasoSURF versus German Gold Standard
NASOSURF VERSUS GERMAN GOLD STANDARD For personal use only NasoSURF vs Pari Sinus IntraNasal Distribution 11
Slide 13: Summary of Near Term Plans
SUMMARY OF NEAR TERM PLANS Launch Maxigesic in new countries For personal use only Advance Maxigesic registrations in North America Further licensing agreements Advance clinical studies of key innovative products NasoSURF clinical trials with pilot devices Achieve first registrations for NasoSURF as
AFT Pharmaceuticals — Investor Presentation (June 2016) on 6ix